KalVista Pharmaceuticals Welcomes New CFO for Future Growth
Company Announcements

KalVista Pharmaceuticals Welcomes New CFO for Future Growth

KalVista Pharmaceuticals ( (KALV) ) just unveiled an announcement.

KalVista Pharmaceuticals, Inc. has appointed Brian Piekos as the new Chief Financial Officer. With over 25 years in the biopharmaceutical industry, Piekos is equipped with a vast experience, having served in similar roles at Elicio Therapeutics, Gemini Therapeutics, and AMAG Pharmaceuticals. His track record in financial and strategic planning is expected to be pivotal as KalVista prepares for the commercial launch of sebetralstat, a novel therapy for hereditary angioedema. His appointment includes a comprehensive compensation package, including a base salary, bonus target, and stock options, alongside severance benefits that align with his new role.

See more insights into KALV stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskKalVista Pharmaceuticals Announces $60 Million Funding Initiatives
TheFlyKalVista enters synthetic royalty financing with DRI Healthcare Trust
TipRanks Auto-Generated NewsdeskKalVista Secures $184M Financing for Sebetralstat Launch
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App